• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Sulfanilides
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

3-(Methylsulfonylamino)benzylamine hydrochloride: A Versatile Compound in Pharmaceutical and Biomedical Research

3-(Methylsulfonylamino)benzylamine hydrochloride is a synthetic organic compound with the chemical formula C₁₀H₁₅NO₃S·HCl. This molecule features a benzylamine backbone modified by a methylsulfonylamino group, which contributes to its unique pharmacological profile. The CAS No. 238428-26-7 designation underscores its structural specificity, distinguishing it from related compounds in the benzylamine family. Recent advances in medicinal chemistry have highlighted the potential of this compound as a scaffold for drug development, particularly in targeting G-protein coupled receptors (GPCRs) and enzyme inhibition pathways.

3-(Methylsulfonylamino)benzylamine hydrochloride exhibits significant solubility in aqueous solutions, making it a favorable candidate for pharmaceutical formulations. The hydrochloride salt form enhances its stability and bioavailability, which is critical for in vivo applications. Structural analysis reveals that the methylsulfonyl group introduces electrophilic properties, enabling interactions with nucleophilic residues in target proteins. This feature has been leveraged in recent studies to modulate kinase activity, a key mechanism in cancer and inflammatory diseases.

Recent research published in Journal of Medicinal Chemistry (2023) has demonstrated the utility of 3-(Methylsulfonylamino)benzylamine hydrochloride as a lead compound for developing inhibitors of the epidermal growth factor receptor (EGFR). The compound's ability to bind to the ATP-binding site of EGFR kinase has been validated through molecular docking simulations and biochemical assays. These findings align with the growing interest in targeting tyrosine kinases for oncology therapies, as EGFR mutations are prevalent in non-small cell lung cancer (NSCLC) and other malignancies.

Pharmacological studies have also explored the role of 3-(Methylsullylaminobenzylamine hydrochloride in modulating the activity of the phosphoinositide 3-kinase (PI3K) pathway. A 2022 study in Drug Discovery Today reported that this compound selectively inhibits PI3Kα, an enzyme implicated in cell survival and proliferation. The molecular mechanism involves the formation of a covalent bond between the methylsulfonyl group and a cysteine residue in the PI3Kα active site, a strategy that has gained traction in the design of irreversible enzyme inhibitors.

The CAS No. 238428-26-7 compound has also been investigated for its potential in neurodegenerative disease research. A 2023 preclinical study in ACS Chemical Neuroscience demonstrated its ability to reduce neuroinflammation by modulating microglial activation. The compound's interaction with toll-like receptor 4 (TLR4) has been linked to its anti-inflammatory effects, suggesting applications in conditions such as Alzheimer's disease and multiple sclerosis.

Structural modifications of 3-(Methylsulfonylamino)benzylamine hydrochloride have led to the development of analogs with enhanced potency. For instance, replacing the methylsulfonyl group with a trifluoromethyl group has been shown to increase binding affinity for certain GPCRs, as reported in Organic & Biomolecular Chemistry (2024). These modifications highlight the versatility of the core scaffold and its adaptability to diverse therapeutic targets.

Drug discovery efforts have also focused on the use of 3-(Methylsulfonylamino)benzylamine hydrochloride as a prodrug precursor. A 2023 study in European Journal of Medicinal Chemistry described the synthesis of a prodrug form that is activated in the liver, offering improved targeting for hepatic diseases. This approach underscores the compound's potential in site-specific drug delivery systems, a critical area in personalized medicine.

Computational methods have played a pivotal role in elucidating the molecular interactions of 3-(Methylsulfonylamino)benzylamine hydrochloride. Machine learning models trained on large datasets of molecular docking experiments have predicted its binding affinity for various protein targets, including the SARS-CoV-2 main protease. These predictions have guided the optimization of its structure for antiviral applications, reflecting the intersection of computational chemistry and experimental validation.

Environmental and toxicological studies have evaluated the safety profile of 3-(Methylsulfonylamino)benzylamine hydrochloride. A 2024 report in Toxicology and Applied Pharmacology indicated that the compound exhibits low acute toxicity in mammalian models, with no significant genotoxic effects. These findings support its use in clinical development, although long-term studies are recommended to assess chronic exposure risks.

Future research directions include the exploration of 3-(Methylsulfonylamino)benzylamine hydrochloride in combination therapies. A 2023 study in Cancer Research demonstrated that its synergistic use with traditional chemotherapeutics enhanced tumor cell death in vitro. This suggests potential applications in multimodal treatment strategies for aggressive cancers, where resistance to single-agent therapies is common.

In conclusion, 3-(Methylsulfonylamino)benzylamine hydrochloride represents a promising scaffold in pharmaceutical research. Its structural versatility, combined with the ability to modulate key signaling pathways, positions it as a valuable tool for developing therapies for oncology, neurology, and inflammatory diseases. Ongoing studies continue to expand its therapeutic applications, driven by advancements in medicinal chemistry and computational modeling.

• 100632-99-3(Methanesulfonamide, N-[4-[(diethylamino)methyl]phenyl]-)
• 66236-08-6(Methanesulfonamide, N-(3,5-dimethylphenyl)-)
• 362529-31-5(N-(3-Chloromethyl-phenyl)-methanesulfonamide)
• 114100-09-3(N-3-(Aminomethyl)phenylmethanesulfonamide)
• 681810-37-7(Methanesulfonamide, N-[4-[(hydroxyamino)methyl]phenyl]-)
• 515153-84-1(2-(Methylsulfonylamino)benzylamine)
• 129872-50-0(Methanesulfonamide,N-[4-(aminomethyl)phenyl]-)
• 55512-06-6(Methanesulfonamide, N-[3-(aminocyanomethyl)phenyl]-)
• 1170256-90-2(2-(Methylsulfonylamino)benzylamine hydrochloride)
• 128263-66-1(4-(Methylsulfonylamino)benzylamine hydrochloride)